The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.

Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Ongoing discussions with the FDA regarding nrSPMS application have indicated ...

Current rules allow India to tax gains only if a French investor holds more than 10% in an Indian company. The revised treaty ...

If Paramount’s $30-per-share, all-cash bid worth $108 billion (including debt) for complete ownership of WBD succeeds, it’ll ...

Federal health officials are reviewing the safety of two injectable drugs used to protect babies and toddlers from the RSV ...

The Food and Drug Administration has launched a safety review of two approved RSV drugs for infants, the latest immunizations ...

US advisers end universal newborn hepatitis B vaccination, sparking backlash from medical experts who warn the move will ...

Interestingly, despite the autumn’s upward trend, November’s haul is the first in 2025 that doesn’t outweigh the ...

Get all of the latest breaking local and international news stories as they happen, with up to the minute updates and analysis, from Ireland's National Broadcaster ...

France's financial fraud office launched a raid on Sanofi's headquarters in Paris as part of an investigation into a financing deal provided by French bank Société Générale. The Parquet National ...

Sanofi delivered strong Q3 results despite currency headwinds. The company's dependence on Dupixent is increasing. A broad immunology pipeline and the Blueprint Medicines acquisition should help ...